Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic, Inc.    

MEDTRONIC, INC.
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Medtronic, Inc. : Medtronic Endurant® AAA Stent Graft Shows Durable Performance at Two Years in U.S. Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:05pm CEST

Market-Leading Medical Device for Minimally Invasive Treatment of Abdominal Aortic Aneurysms Continues to Demonstrate Strong Safety and Efficacy

Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE:MDT) announced yesterday the two-year results from its U.S. clinical study of the Endurant AAA Stent Graft System, the global market leader in its product category.

Presented at this year's Charing Cross International Symposium (CX34) in London, the prospective Endurant U.S. investigational device exemption (IDE) study's complete results at two years continue to demonstrate durable clinical performance with strong safety and efficacy in long-term follow-up. These results add to a growing body of evidence on the Endurant AAA Stent Graft, which continues to deliver consistent clinical results in both controlled trials and real-world registries.

"The Endurant Stent Graft is performing just as well at two years as it did at one year, with no aneurysm-related mortalities, migrations or conversions," said the study's principal investigator, Dr. Michel Makaroun, professor and chief of vascular surgery at the University of Pittsburgh School of Medicine. "Freedom from aneurysm-related mortality and secondary interventions demonstrate favorable trends versus earlier generation devices. This finding will continue to play a critical role in improving the minimally-invasive treatment of patients with abdominal aortic aneurysms."

The Endurant U.S. IDE study enrolled 150 AAA patients at 26 U.S. medical centers. Significant to clinical practice, the study included patients with "landing zones," or healthy aortic neck lengths, as short as 10 mm, whereas most other trials of aortic stent grafts have required neck lengths of at least 15 mm. The study also monitored changes in aneurysm size and stent graft migration, a concern with current endovascular treatment, as well as the occurrence and type of endoleaks.

The study found that nearly all (97.6 percent) of the aneurysm sacs that were treated with the Endurant AAA Stent Graft decreased or remained stable in size at two years post-procedure, with only 0.8 percent Type I endoleaks and no Type III endoleaks.

In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.

ABOUT MEDTRONIC

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology -- alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Medtronic, Inc.
Public Relations
Joe McGrath, 707-591-7367
Investor Relations
Jeff Warren, 763-505-2696


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC, INC.
01:06p MEDTRONIC : Announces Clinical Study to Evaluate the CoreValve Evolut PRO System..
09/23 MEDTRONIC : MDT) Reports Clinical Study to Evaluate the CoreValve Evolut PRO Sys..
09/22 MEDTRONIC : Announces Clinical Study to Evaluate CoreValve(TM) Evolut(TM) PRO Sy..
09/21 MEDTRONIC : Announces Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) PR..
09/21 MEDTRONIC : Source Sought Notice - Medtronic Cardiac and Neurological Implants
09/21 Hurricane Maria forces Medtronic to close Puerto Rico manufacturing plants
09/20 MEDTRONIC : Announces FDA Approval and U.S. Launch of Next Generation Spinal Cor..
09/19 MEDTRONIC : Federal Contracts Awarded by Federal Agencies in Iowa (Sept. 19)
09/18 MEDTRONIC : Fusion Software Support Program Renewal
09/18 MEDTRONIC : Q-- Medtronic - Fusion Software Support Program Renewal
More news
News from SeekingAlpha
2015 DIVIDEND INCOME UPDATE : January 2015
2015 FDA clears Medtronic transcatheter heart valve
2015 Dividend Aristocrats And A Fundamental Principle Of Dividend Growth Investing
2015 Boston Scientific Awaits Court Decision
2015 The DGI 'Factual 48' Versus 'The Favored 44'
Financials ($)
Sales 2018 29 468 M
EBIT 2018 8 505 M
Net income 2018 4 272 M
Debt 2018 16 479 M
Yield 2018 2,32%
P/E ratio 2018 23,01
P/E ratio 2019 19,97
EV / Sales 2018 4,22x
EV / Sales 2019 4,00x
Capitalization 108 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 91,1 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Mark Ploof Senior Vice President-Global Operations
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC, INC.107 961
MEDTRONIC PLC11.65%107 961
BAXTER INTERNATIONAL43.23%34 605
C R BARD INC41.83%23 155
ZIMMER BIOMET HOLDINGS INC10.85%23 131
HOYA CORPORATION23.29%21 111